The injectables segment by procedure is estimated to lead the market growth during the forecast period.
According to a new market research study of “Asia Pacific Non-Invasive Aesthetic Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Procedure, End-user and Country.” The Asia Pacific non-invasive aesthetic treatment market is expected to reach US$ 3,927.20 million by 2028 from US$ 1,470.31 million in 2021; it is estimated to grow at a CAGR of 15.1% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific non-invasive aesthetic treatment market and the factors driving market along with those that act as hindrances.
The Asia Pacific non-invasive aesthetic treatment market based on the procedure was segmented into injectables, skin rejuvenation, and others. In 2020, the injectables segment held the largest share of the market, and same segment is expected to grow at the fastest rate during the coming years.
Non-invasive aesthetic treatments have gained popularity in the past few years due to advantages such as minimal downtime, no scars, low cost, and less complications. The popularity and acceptance of these procedures is mainly attributed to their non-invasiveness. Besides, it has been proved that the accuracy rate of minimally invasive surgeries is greater than that of open surgeries. Non-surgical cosmetic procedures do not involve making surgical incisions and usually are considered minimally invasive. Several manufacturers are working on advanced non-invasive aesthetic treatment products. In October 2020, Alma launched its latest Alma Hybrid platform, designed to explore multiple possibilities of using ablative, non-ablative, and thermal treatments, along with testing their synergistic impact, on skin rejuvenation and scar revision. Therefore, the availability of user-friendly, technologically advanced non-invasive aesthetic treatment products is fuelling the growth of the Asia Pacific non-invasive aesthetic treatment market. On the other hand, continuously upgrading technology landscape creates a room for improvements in the existing products. This provides significant opportunities to dermatological and medical platform providers to bring innovations in their offerings. Moreover, the demand for customized treatment options has always served wider growth opportunities for market players. Therefore, ongoing technological developments in laser systems and prospering medical tourism sector are offering significant opportunities for the future growth of Asia Pacific aesthetic laser treatment market players.
Countries in Asia-Pacific are witnessing massive challenges due to the growing COVID-19 cases. To prevent the spread of virus, restrictive measures have been taken in countries such as India, South Korea, Singapore, Malaysia, and the Philippines. Considering the economic operations and geographic condition, the outbreak has affected medical tourism and manufacturing of medical equipment, laser systems, accessories. Asia-Pacific low-income countries are experiencing the shortage of healthcare infrastructure. Also, the ongoing COVID-19 pandemic has created a seismic shift in living and cosmetic habits in the region, and the beauty industry has borne a significant brunt of this shopper shake-up. This scenario is likely to have negative impact on the non-invasive aesthetic treatment market in Asia Pacific countries.
The growth of the market is attributed to a few key driving factors such as availability of technologically advanced products and proliferation of medical tourism across developing countries. However, clinical risks and complications associated with medical aesthetic procedures are hindering the market growth.
Galderma, Alma Lasers, Merz Pharma, Bausch Health Companies Inc. Cutera Inc. AbbVie Inc. Candela Medical and Johnson and Johnson Services, Inc. are among the leading companies operating in the Asia Pacific non-invasive aesthetic treatment market.
The Asia Pacific non-invasive aesthetic treatment market based on the procedure was segmented into injectables, skin rejuvenation, and others. In 2020, the injectables segment held the largest share of the market, and same segment is expected to grow at the fastest rate during the coming years.
Non-invasive aesthetic treatments have gained popularity in the past few years due to advantages such as minimal downtime, no scars, low cost, and less complications. The popularity and acceptance of these procedures is mainly attributed to their non-invasiveness. Besides, it has been proved that the accuracy rate of minimally invasive surgeries is greater than that of open surgeries. Non-surgical cosmetic procedures do not involve making surgical incisions and usually are considered minimally invasive. Several manufacturers are working on advanced non-invasive aesthetic treatment products. In October 2020, Alma launched its latest Alma Hybrid platform, designed to explore multiple possibilities of using ablative, non-ablative, and thermal treatments, along with testing their synergistic impact, on skin rejuvenation and scar revision. Therefore, the availability of user-friendly, technologically advanced non-invasive aesthetic treatment products is fuelling the growth of the Asia Pacific non-invasive aesthetic treatment market. On the other hand, continuously upgrading technology landscape creates a room for improvements in the existing products. This provides significant opportunities to dermatological and medical platform providers to bring innovations in their offerings. Moreover, the demand for customized treatment options has always served wider growth opportunities for market players. Therefore, ongoing technological developments in laser systems and prospering medical tourism sector are offering significant opportunities for the future growth of Asia Pacific aesthetic laser treatment market players.
Countries in Asia-Pacific are witnessing massive challenges due to the growing COVID-19 cases. To prevent the spread of virus, restrictive measures have been taken in countries such as India, South Korea, Singapore, Malaysia, and the Philippines. Considering the economic operations and geographic condition, the outbreak has affected medical tourism and manufacturing of medical equipment, laser systems, accessories. Asia-Pacific low-income countries are experiencing the shortage of healthcare infrastructure. Also, the ongoing COVID-19 pandemic has created a seismic shift in living and cosmetic habits in the region, and the beauty industry has borne a significant brunt of this shopper shake-up. This scenario is likely to have negative impact on the non-invasive aesthetic treatment market in Asia Pacific countries.
The growth of the market is attributed to a few key driving factors such as availability of technologically advanced products and proliferation of medical tourism across developing countries. However, clinical risks and complications associated with medical aesthetic procedures are hindering the market growth.
Galderma, Alma Lasers, Merz Pharma, Bausch Health Companies Inc. Cutera Inc. AbbVie Inc. Candela Medical and Johnson and Johnson Services, Inc. are among the leading companies operating in the Asia Pacific non-invasive aesthetic treatment market.
The report segments in Asia Pacific Non-Invasive Aesthetic Treatment Market as follows:
By Procedure
- Injectables
- Botulinum Toxin
- Calcium Hydroxylapatite
- Hyaluronic Acid
- Polymer Filler
- Collagen
- Skin Rejuvenation
- Chemical Peel
- Laser Skin Resurfacing
- Photorejuvenation
- Others
- Hair Removal
- Nonsurgical Fat Reduction
- Sclerotherapy
- Cellulite Treatment
By End-user
- Hospitals
- Clinics and Medical Spas
- Others
By Country
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific non-invasive aesthetic treatment market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific non-invasive aesthetic treatment market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Frequently Asked Questions about the Asian Pacific Non-Invasive Aesthetic Treatment Market
What is the estimated value of the Asian Pacific Non-Invasive Aesthetic Treatment Market?
What is the growth rate of the Asian Pacific Non-Invasive Aesthetic Treatment Market?
What is the forecasted size of the Asian Pacific Non-Invasive Aesthetic Treatment Market?
Who are the key companies in the Asian Pacific Non-Invasive Aesthetic Treatment Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 158 |
| Published | July 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 1470.31 Million |
| Forecasted Market Value ( USD | $ 3927.2 Million |
| Compound Annual Growth Rate | 15.1% |
| Regions Covered | Asia Pacific |
Table of Contents
1. Introduction
3. Research Methodology
4. Asia Pacific Non-invasive Aesthetic Treatment Market Market Landscape
5. Non-Invasive Aesthetic Treatment Market - Key Market Dynamics
6. Non-invasive Aesthetic Treatment Market - Asia Pacific Analysis
7. Non-invasive Aesthetic Treatment Market Analysis - By Procedure
8. Non-invasive Aesthetic Treatment Market Analysis - By End User
9. Non-invasive Aesthetic Treatment Market - Asia Pacific Analysis
10. Impact Of COVID-19 Pandemic on Asia Pacific Non-invasive Aesthetic Treatment Market
11. Non-invasive Aesthetic Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Galderma
- Alma Lasers
- Merz Pharma
- Bausch Health Companies Inc.
- Cutera Inc.
- AbbVie Inc.
- Candela Medical
- Johnson and Johnson Services, Inc.
